# Safety and Efficacy Study of VIS649 for IgA Nephropathy

> **NCT04287985** · PHASE2 · COMPLETED · sponsor: **Otsuka Pharmaceutical Development & Commercialization, Inc.** · enrollment: 155 (actual)

## Conditions studied

- Immunoglobulin A Nephropathy
- Glomerular Disease
- IgAN

## Interventions

- **DRUG:** Dose-Placebo
- **DRUG:** Low Dose-VIS649
- **DRUG:** Medium Dose-VIS649
- **DRUG:** High Dose-VIS649

## Key facts

- **NCT ID:** NCT04287985
- **Lead sponsor:** Otsuka Pharmaceutical Development & Commercialization, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-07-20
- **Primary completion:** 2023-05-19
- **Final completion:** 2023-06-18
- **Target enrollment:** 155 (ACTUAL)
- **Last updated:** 2026-04-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04287985

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04287985, "Safety and Efficacy Study of VIS649 for IgA Nephropathy". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04287985. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*